Activity

The mean ME and MAE were 1.4, 29.6, 5.4 Hounsfield units (HU) and 77.2, 94.2, 41.8 HU for H&N, thoracic and pelvic region, respectively. Dice similarity coefficients varied between 66.7±8.3% (seminal vesicles) and 94.9±2.0% (lungs). Maximum mean surface distances were 6.3mm (heart), followed by 3.5mm (brainstem). The mean dosimetric differences of the target volumes did not exceed 1.7%. Mean 3D gamma pass rates greater than 97.8% were achieved in all cases.

The presented method generates sCT images with a quality close to pCT and yielded clinically acceptable dosimetric deviations. Thus, an important prerequisite towards clinical implementation of CBCT-based ART is fulfilled.

The presented method generates sCT images with a quality close to pCT and yielded clinically acceptable dosimetric deviations. Thus, an important prerequisite towards clinical implementation of CBCT-based ART is fulfilled.

Low-kV IORT (Low kilovoltage intraoperative radiotherapy) using INTRABEAM machine and dedicated spherical applicators is a candidate modality for breast cancer treatment. The current study aims to quantify the RBE (relative biologic effectiveness) variations of emitted X-rays from the surface of different spherical applicators and bare probe through a hybrid Monte Carlo (MC) simulation approach.

A validated MC model of INTRABEAM machine and different applicator diameters, based on GEANT4 Toolkit, was employed for RBE evaluation. To doing so, scored X-ray energy spectra at the surface of each applicator diameter/bare probe were used to calculate the corresponding secondary electron energy spectra at various distances inside the water and breast tissue. Then, MCDS (Monte Carlo damage simulation) code was used to calculate the RBE values according to the calculated electron spectra.

Presence of spherical applicators can increase the RBE of emitted X-rays from the bare probe by about 22.3%. In return, changing the applicator diameter has a minimal impact (about 3.2%) on RBE variation of emitted X-rays from each applicator surface. By increasing the distance from applicator surface, the RBE increments too, so that its value enhances by about 10% with moving from 2 to 10mm distance. Calculated RBE values within the breast tissue were higher than those of water by about 4% maximum value.

Ball section of spherical IORT applicators can affect the RBE value of the emitted X-rays from INTRABEAM machine. Increased RBE of breast tissue can reduce the prescribed dose for breast irradiation if INTRABEAM machine has been calibrated inside the water.

Ball section of spherical IORT applicators can affect the RBE value of the emitted X-rays from INTRABEAM machine. Increased RBE of breast tissue can reduce the prescribed dose for breast irradiation if INTRABEAM machine has been calibrated inside the water.

To validate the feasibility and accuracy of commonly used collapsed cone (CC) dose engine for Elekta Unity 1.5T MR-LINAC online independent dose verification.

The Unity beam model was built and commissioned in RayStation treatment planning system with CC dose engine. find more Four AAPM TG-119 test plans were created and measured with ArcCHECK phantom for comparison, another thirty patient plans from six tumor sites were also included. The dosimetric criteria for various ROIs and 3D gamma passing rates were quantitatively evaluated, and the effects of magnetic field and dose deposition type on the dose difference between two systems were further analyzed.

ArcCHECK based measurement showed a clear magnetic field induced profile shift between CC with both measurement and GPUMCD. For clinical plans, gamma passing rates with criteria (3%, 3mm) between GPUMCD and CC large than 90% can be achieved for most tumor sites except esophagus and lung cases, the mean dose difference of 3% can be satisfied for most ROIs from all tumor sites. The magnetic field caused a large dose impact on low density areas, the average gamma passing rates were improved from 85.54% to 96.43% and 87.40% to 99.54% for esophagus and lung cases when the magnetic field effect was excluded.

It is feasible to use CC dose engine as a secondary dose calculation tool for Elekta Unity system for most tumor sites, while the accuracy is limited and should be used carefully for low density areas, such as esophagus and lung cases.

It is feasible to use CC dose engine as a secondary dose calculation tool for Elekta Unity system for most tumor sites, while the accuracy is limited and should be used carefully for low density areas, such as esophagus and lung cases.We investigated the dose differences between robust optimization-based treatment planning (4DRO) and range-adapted internal target volume (rITV). We used 4DCT dataset of 20 lung cancer and 20 liver cancer patients, respectively, who had been treated with respiratory-gated carbon-ion pencil beam scanning therapy. 4DRO and rITV plans were created with the same clinical target volume (CTV) and organs at risk (OAR) contours. Four-dimensional dose distribution was calculated using deformable image registration. Dose metrics (e.g. D95, V20) were analyzed. Statistical significance was assessed by the Wilcoxon signed-rank test. For the lung cases, the mean CTV-D95 value for the rITV plan (=98.5%) was same as that for the 4DRO plan (=98.5%, P = 0.106), while the mean D95 value for the CTV + setup margin contour for the rITV plan (=98.2%) was higher than that for the 4DRO plan (95.2%, P less then 0.001). For the liver cases, the mean CTV-D95 value for the rITV plan (=98.1%) was slightly lower than that for the 4DRO plan (=98.5%, P less then 0.01), while the mean D95 value for the CTV + setup margin contour for the rITV plan (=98.0%) was higher than that for the 4DRO plan (94.1%, P less then 0.001). For the doses to the organs at risk (OARs), the ipsilateral lung-V20/liver-V20 values for the rITV plan (=10.1%/19.7%) was significantly higher than that for the 4DRO plan (=8.6%/17.6, P less then 0.001). Although the target coverage for 4DRO plan may be worse than that for rITV plan in the presence of the setup error, the 4DRO plan can improve OAR dose while preserving acceptable target dose coverage.